Literature DB >> 10225232

Feasibility of a preventive HIV-1 vaccine cohort among persons attending sexually transmitted disease clinics in Thailand.

L E Markowitz1, N Sirisopana, A Charonwatanachokchai, W Julvanichpong, T Siraprapasiri, T Palanuvej, P Siriwongrangsun, V Tungsakul, K Pumratana, A Chitwarakorn, R A Michael, A E Brown.   

Abstract

Persons attending sexually transmitted disease clinics at three sites in Thailand were recruited to participate in a 1-year study of HIV-1 incidence. Between September 1995 and February 1996, 31% (371 of 1205) of eligible men and 24% (161 of 659) of eligible women agreed to participate. At enrollment, HIV-1 seropositivity was 3.8% among men and 2.5% among women. Follow-up of the 514 participants who were seronegative at baseline was 78% at the 12-month visit. During the study period, 53% of men reported 2 or more sexual partners, 31% reported sex with a commercial sex worker (CSW), and 33% with a casual partner. Of those visiting CSWs, 72% reported consistent condom use. Among women, 11% reported 2 or more sexual partners. Decreased HIV risk behaviors among men were observed during the study. Four incident infections occurred in men (1.4/100 person-years, 95% confidence interval [CI] = 0.4-3.6) and none among women. Based on the observed HIV-1 incidence, HIV vaccine efficacy trials in such populations would have to be larger than previously planned or more selective of high risk subgroups for recruitment.

Entities:  

Keywords:  Acquired Immunodeficiency Syndrome; Asia; Clients; Clinical Research; Clinical Trials; Cohort Analysis; Developing Countries; Diseases; Hiv Infections; Incidence; Infections; Measurement; Organization And Administration; Prevalence; Program Activities; Programs; Reproductive Tract Infections; Research Methodology; Research Report; Sexually Transmitted Diseases; Southeastern Asia; Thailand; Vaccines; Viral Diseases

Mesh:

Substances:

Year:  1999        PMID: 10225232     DOI: 10.1097/00042560-199904150-00012

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr Hum Retrovirol        ISSN: 1077-9450


  3 in total

Review 1.  Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV.

Authors:  Monica Vaccari; Poonam Poonam; Genoveffa Franchini
Journal:  Expert Rev Vaccines       Date:  2010-09       Impact factor: 5.217

2.  Are women who work in bars, guesthouses and similar facilities a suitable study population for vaginal microbicide trials in Africa?

Authors:  Andrew Vallely; Ian R Hambleton; Stella Kasindi; Louise Knight; Suzanna C Francis; Tobias Chirwa; Dean Everett; Charles Shagi; Claire Cook; Celia Barberousse; Deborah Watson-Jones; John Changalucha; David Ross; Richard J Hayes
Journal:  PLoS One       Date:  2010-05-14       Impact factor: 3.240

3.  Enhanced retention strategies and willingness to participate among hard-to-reach female sex workers in Barcelona for HIV prevention and vaccine trials.

Authors:  M Florencia Etcheverry; Jennifer L Evans; Emilia Sanchez; Eva Mendez-Arancibia; Mercé Meroño; José M Gatell; Kimberly Page; Joan Joseph
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.